Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pro-Inflammatory Vicious Cycle-Normalizing Biomimetic Nanoparticles to Treat Acute Respiratory Distress Syndrome.

Advanced healthcare materials·2026
Same author

Genome-wide association study identifies loci controlling grain yield and protein content in mungbean (Vigna radiata (L.) R. Wilczek var. radiata) using DArTseq SNP markers.

BMC plant biology·2026
Same author

Electrical and chemical synapses share similar organizational principle.

bioRxiv : the preprint server for biology·2026
Same author

Uncovering the electrical synapse proteome in retinal neurons via in vivo proximity labeling.

eLife·2026
Same author

Room-Temperature Alane Dehydrogenation for Visible-Light-Driven Photocatalytic Hydrogen Supply System.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Mitochondria-targeted gene delivery using fluorinated lipid nanoparticles to alleviate Leber's hereditary optic neuropathy.

Nature communications·2025

Related Experiment Video

Updated: Jun 27, 2026

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

Clearing the Pulmonary Traffic Jam With Dual-Enzyme Inhalable Nanoparticles Restore Airflow and Reverse Fibrotic

Xue-Na Li1,2, Xi-Xi Ma3, Ya-Ping Lin3

  • 1Affiliated Jiangning Hospital of Chinese Medicine, China Pharmaceutical University, Nanjing, China.

Advanced Healthcare Materials
|June 26, 2026
PubMed
Summary
This summary is machine-generated.

New inhalable nanoparticles deliver drugs effectively for idiopathic pulmonary fibrosis (IPF) by breaking down mucus and extracellular matrix barriers. This approach enhances drug delivery and restores lung function in fibrosis models.

Keywords:
dual‐enzyme modificationextracellular matrix penetrationmicroenvironment remodelingmucus viscositypulmonary traffic jam

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Related Experiment Videos

Last Updated: Jun 27, 2026

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Area of Science:

  • Nanotechnology
  • Pulmonary Drug Delivery
  • Biomedical Engineering

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by mucus hypersecretion and extracellular matrix (ECM) deposition.
  • These pathological changes create physical barriers that impede effective pulmonary drug delivery, limiting current therapeutic options.
  • Inhalation therapy faces challenges due to mucus and ECM accumulation, which restrict drug penetration and retention in lung tissue.

Purpose of the Study:

  • To develop dual-enzyme-modified inhalable nanoparticles to overcome pulmonary physical obstructions in IPF.
  • To enhance the delivery and efficacy of pirfenidone (PFD) for treating lung fibrosis.
  • To investigate an enzyme-mediated strategy for remodeling the lung microenvironment.

Main Methods:

  • Co-functionalization of liposomal nanoparticles with bromelain and collagenase (Lipo/PFD-CB).
  • Bromelain was used to reduce mucus viscosity by cleaving mucin crosslinks.
  • Collagenase was employed to degrade ECM fibers, facilitating drug penetration and retention.
  • Evaluation in bleomycin-induced lung fibrosis models (early and advanced stages).

Main Results:

  • Dual-enzyme modification significantly improved aerosol deposition efficiency to 86.5%.
  • The nanoplatform optimized the pharmacokinetic profile and tissue distribution of pirfenidone.
  • Lipo/PFD-CB treatment attenuated profibrotic cellular activation and restored alveolar architecture and airflow in fibrosis models.

Conclusions:

  • Enzyme-mediated remodeling of the lung microenvironment effectively clears physical obstructions, termed 'pulmonary traffic jams'.
  • This nanoplatform enhances therapeutic outcomes for idiopathic pulmonary fibrosis by improving drug delivery and restoring lung homeostasis.
  • The study presents a promising strategy for enhancing pulmonary drug delivery in fibrotic lung diseases.